Mhd Yaser Al-Marrawi

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

Mhd Yaser Al-Marrawi, Brian I. Rini, Lauren C. Harshman et al. · Targeted Oncology · 2013 · 49 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer

Mhd Yaser Al-Marrawi, Bikramajit Singh Saroya, Matthew Brennan et al. · Cancer Biology & Therapy · 2013 · 34 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts).

Mhd Yaser Al-Marrawi, Brian I. Rini, Lauren C. Harshman et al. · Journal of Clinical Oncology · 2011 · 15 citations

Medicine, Oncology, Pharmacotherapy +15